Comments from Decision Resources Group Analysts:
- "Although all EU5 markets respond to EMA approval with national-level reimbursement negotiations, there can be considerable market access variation at the regional level within these markets. Marketing to physicians and negotiating local discounts will be critical to increase uptake of newer therapies." Kristine Mackin, Ph.D.
- "Germany's HTA review of Nucala (GlaxoSmithKline) underscores the importance of demonstrating superiority to existing treatments. While the emerging asthma biologics will compete for share of the underserved severe, refractory market, Xolair (Roche/Novartis) and all new biologics are perceived to target a largely overlapping patient population, and thus in the absence of head-to-head trials, their developers will have difficulty in negotiating price premiums relative to the competitor brands. Too high a premium is likely to result in stringent payer-imposed controls and possible exclusion from reimbursement." Elena Kozhemyakina, Ph.D.
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-eu5-market-for-respiratory-drugs-is-becoming-increasingly-crowded-and-price-sensitive-300292635.html
SOURCE Decision Resources Group